Skip to main content
Premium Trial:

Request an Annual Quote

Court Approves Vermillion's Plan of Reorganization; Company Raises $43M

Premium

Vermillion's Chapter 11 reorganization plan was approved by US Bankruptcy Court in Delaware on Thursday, the company announced.

As a result, the company will launch head-first into efforts to commercialize its OVA1 tumor triage diagnostic for ovarian cancer with Quest Diagnostics. The test received 510(k) clearance from the US Food and Drug Administration in September and the court's approval of Vermillion's reorganization plan had been expected.

Vermillion filed for Chapter 11 protection in late March.

The court's approval also frees up the company to proceed with the development of other tests in its R&D pipeline, including additional diagnostics for ovarian cancer, as well as tests for thrombocytopenic purpura and peripheral artery disease.

Earlier in the week, Vermillion's unsecured creditors had approved the reorganization plan, paving the way for Bankruptcy Court to give the plan its thumbs up.

In anticipation of the plan's approval, Vermillion has been raising funds. It announced separately on Thursday the closing of a private placement of stock with a group of investors that raised $43 million in gross proceeds.

The transaction resulted in the sale of about 2.3 million shares of its common stock at a price of approximately $18.5 per share.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.